Bley Carla Rohrer, Roos Malgorzata, Price Jill, Ruess-Melzer Katja, Buchholz Julia, Poirier Valerie, Kaser-Hotz Barbara
Section of Diagnostic Imaging and Radiation Oncology, Vetsuisse Faculty, University of Zurich, CH-8006 Zurich, Switzerland.
J Am Vet Med Assoc. 2007 Nov 1;231(9):1347-53. doi: 10.2460/javma.231.9.1347.
To assess the effects of repeated episodes of propofol-associated anesthesia on quality of recovery from anesthesia, clinical status, and erythrocyte physiology in cats.
Original study.
37 cats undergoing short-duration anesthesia for radiotherapy.
Twice daily on 5 consecutive days, 13 cats with squamous cell carcinoma of the nasal planum (group 1) underwent anesthesia: first via administration of propofol or a midazolam (0.2 mg/kg [0.09 mg/lb])-propofol combination and then via administration of ketamine and midazolam each day (latter data were not analyzed). During a 19-day period, 24 cats with vaccine associated sarcoma (group 2) were anesthetized 12 times with propofol or a midazolam-propofol combination. Anesthesia was maintained with propofol in both groups. Hematologic analysis was performed before, during, and on completion of radiotherapy; changes in Hct and hemoglobin concentration between groups were compared.
Mean duration of anesthesia was 8.1 minutes (range, 5 to 20 minutes); no adverse events were detected during recovery. Total dose of propofol administered did not differ between groups 1 (6.34 mg/kg [2.88 mg/lb]) and 2 (4.71 mg/kg [2.14 mg/lb]). Midazolam administration decreased the propofol dose by 26%. Overall decreases from baseline in Hct and hemoglobin concentration were not significantly different between the 2 groups, nor clinically important; however, compared with baseline, values in group 2 were significantly lower after 6 and 12 anesthetic episodes for both protocols. Heinz bodies were identified in low numbers in both groups during radiotherapy.
Results indicated that repeated propofol-associated short-duration anesthesia does not lead to clinically relevant hematologic changes in cats undergoing short-duration radiotherapy.
评估多次丙泊酚相关麻醉对猫麻醉恢复质量、临床状态及红细胞生理学的影响。
原创性研究。
37只接受短期放疗麻醉的猫。
连续5天每天2次，13只患有鼻平面鳞状细胞癌的猫（第1组）接受麻醉：首先给予丙泊酚或咪达唑仑（0.2 mg/kg [0.09 mg/lb]）-丙泊酚联合用药，然后每天给予氯胺酮和咪达唑仑（后一组数据未分析）。在19天期间，24只患有疫苗相关肉瘤的猫（第2组）用丙泊酚或咪达唑仑-丙泊酚联合用药麻醉12次。两组均用丙泊酚维持麻醉。在放疗前、放疗期间及放疗结束时进行血液学分析；比较两组间血细胞比容（Hct）和血红蛋白浓度的变化。
平均麻醉持续时间为8.1分钟（范围为5至20分钟）；恢复期间未检测到不良事件。第1组（6.34 mg/kg [2.88 mg/lb]）和第2组（4.71 mg/kg [2.14 mg/lb]）给予的丙泊酚总剂量无差异。咪达唑仑给药使丙泊酚剂量降低了26%。两组Hct和血红蛋白浓度较基线的总体降低无显著差异，临床上也无重要意义；然而，与基线相比，两种方案在第6次和第12次麻醉后第2组的值均显著降低。放疗期间两组均发现少量海因茨小体。
结果表明，多次丙泊酚相关的短期麻醉不会导致接受短期放疗的猫出现临床上相关的血液学变化。
